Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesNew directions in the treatment of systemic lupus erythematosus
Current Medical Research and Opinion, 07/01/09
Kalunian K et al. – Biologic compounds that target specific immunologic mechanisms offer a new paradigm in the treatment of systemic lupus erythematosus (SLE); may reverse the course of the disease and might provide some new alternatives to reduce symptoms and limit tissue damage without undue contribution to overall morbidity and mortality.
Methods- Review to provide an up-to-date overview of:
- Treatment approaches for SLE, highlighting the multiplicity and heterogeneity of clinical symptoms that underlie therapeutic decisions
- Currently available therapies, their mechanisms and associated side-effects
- Recent developments with biologic treatments including rituximab, epratuzumab, TNF inhibitors, and belimumab
- MEDLINE literature search for ‘SLE’ and ‘damage’ and ‘treatment’ was undertaken for 1996–2008
- Secondary citations obtained from selected manuscripts
- Individual case studies were excluded
- SLE is an autoimmune disease involving multiple organ systems, a clinical pattern of flares and remissions, and the presence of ANA
- Early symptoms involve skin and joints
- Disease morbidity and mortality are associated with CV events and damage to major organs, particularly the kidneys
- Many of the current therapeutic options are considered to be inadequate because of toxicities, organ damage, and insufficient control of disease
- New treatments are mainly focused on the targeted immunosuppressive actions provided by biologic therapy
- Although their long-term beneficial or harmful effects are unclear, their precise molecular targeting may advance the cause of individualized molecular medicine
Today in Systemic Lupus (SLE)...keeping you current
Receive free subspecialty "5-minute updates" via email
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
Kidney International, 11/05/09
Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus. A randomized controlled trial
Annals of Rheumatic Diseases, 11/10/09
Influence of race/ethnicity on response to lupus nephritis treatment: The ALMS study
Rheumatology, 11/24/09
Sponsor
Article Search
Sponsor